Activated Prothrombin Complex Concentrate for coagulopathy reversal secondary to ischemic hepatic injury due to cardiac tamponade: A case report

Hassan Mitwally\textsuperscript{a,*}, Alaa Rahhal\textsuperscript{b}, Amr Fahmi\textsuperscript{a}, Dore Ananthegowda\textsuperscript{c}

\textsuperscript{a} Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar
\textsuperscript{b} Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
\textsuperscript{c} Critical Care Department, Al-Wakra Hospital, Hamad Medical Corporation, Doha, Qatar

**ARTICLE INFO**

Article history:
Received 11 February 2021
Received in revised form 27 February 2021
Accepted 28 February 2021
Available online 5 March 2021

Keywords:
Cardiac tamponade
Pericardiocentesis
Prothrombin Complex Concentrate
Coagulopathy

**ABSTRACT**

**INTRODUCTION AND IMPORTANCE:** Correction of coagulopathy is needed before invasive procedures. However, there is limited evidence to support using Prothrombin Complex Concentrate (PCC) to reverse coagulopathy secondary to liver disease.

**CASE PRESENTATION:** We report a case of a 68-year-old male patient a known case of heart failure with preserved ejection fraction, who developed cardiac tamponade, resulting in hemodynamic instability and ischemic liver injury leading to coagulopathy of INR 2.3. Activated PCC (FEIBA) was used to reverse coagulopathy. INR dropped to 1.9 and the procedure was performed uneventfully with successful elimination of tamponade signs evidenced by echocardiography.

**CLINICAL DISCUSSION:** In this case, the patient required an urgent pericardiocentesis. Activated PCC used successfully to reverse coagulopathy, which was important prior to the procedure.

**CONCLUSION:** In view of the need for urgent pericardiocentesis, coagulopathy due to ischemic liver injury could be reversed with the use of activated PCC.

© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Ischemic hepatitis occurs due to decreased systemic blood flow and hypo-perfusion, resulting in coagulopathy due to impaired production of coagulation factors [1–3]. Correction of coagulopathy is needed before invasive procedures. However, there has been limited evidence to support using Prothrombin Complex Concentrate (PCC) to reverse coagulopathy secondary to liver disease. The use of Kcentra, which is an inactivated 4 factor PCC that contains heparin, was evaluated among patients with liver disease, while the use of FEIBA, an activated PCC, among patients with ischemic liver disease induced coagulopathy has not been evaluated yet [4]. To the best of our knowledge, this is the first case report in the medical literature that used FEIBA to correct hepatic induced coagulopathy pre-procedure.

2. Case presentation

A 68-year-old male patient with a history of diabetes mellitus type II, hypertension, chronic kidney disease stage 5, and heart failure with preserved ejection fraction (Grade III). The patient was admitted to our hospital with shortness of breath and generalized body aches secondary to worsening of kidney function (from 245 umol/L, 1 month before admission to 469 upon admission). Because of progressive worsening of kidney function despite being on diuretic therapy, he underwent one session of hemodialysis on day 11 of hospitalization.

On day 22, late night, the patient started to be hypotensive 87/57 mmHg and lethargic with a decrease in urine output. The patient was shifted to the MICU (medical intensive care unit), a bolus of crystalloids was given, and started on a norepinephrine infusion to keep mean arterial blood pressure (MAP) ≥ 65 mmHg. Echo was done on the same day and showed moderate pericardial effusion, which was more on the lateral and posterior wall and was also evident in the apical wall; this effusion was not there when Echo was performed on admission. A subcostal approach was planned, but due to coagulopathy and hepatomegaly, which increased the risk of bleeding for the patient; therefore, an apical approach was agreed upon. Since his international normalized ratio (INR) was 1.7 as shown in Table 1, four units of Fresh Frozen Plasma (FFP) were given.

On day 2 of MICU admission, the vasopressors requirements increased with an increase in lactate to 8 mmol/L at 09:00, and the patient became anuric, and continuous renal replacement therapy started. Additionally, his liver enzymes, alanine aminoo-
transerase, and aspartate aminotransferase, increased to 1729 U/L and 1772 U/L, respectively, with an increase in INR to 2 as shown in Table 2. Therefore, he was diagnosed with acute ischemic hepatits complicated by coagulopathy. In view of the increase in lactate and vasopressors requirements, emergency pericardiocentesis was decided to be done after the correction of coagulopathy. At 10:00, another four units of FFP were given with 10 mg of vitamin K.

The advanced cardiac monitoring device was connected after femoral line insertion, which showed a cardiac index of 0.9 L/min/m2, systemic vascular resistance of >4000 dynes/sec/cm5, and a confirmed cardiogenic shock secondary to cardiac tamponade was established. A repeated coagulation profile was done and revealed an increase in INR to 2.3, which showed no response to FFP administration. In view of the critical situation and the need for emergency pericardiocentesis, it was decided to give activated prothrombin complex concentrate (FEIBA) 2500 units as an intermittent infusion over 20 min. Following administration, the coagulation profile was repeated within 1 h and revealed a decrease in INR to 1.9, as demonstrated in Fig. 1. Once the INR was below 2, a pre-pericardiocentesis echo was done and showed an increase in the pericardial effusion, a collapse in the right ventricle and right atrium; an apical approach was adopted which was done with echocardiographic guidance and 60 mL of fluid was drained and sent to the lab for tests. The procedure was done by the attending cardiologist. There was no significant bleeding and a follow-up echo showed improvement in signs of tamponade and a draining catheter was secured in position.

After pericardiocentesis by a short time, the patient’s hemodynamics deteriorated again. At 21:20, the patient developed asystole cardiac arrest, and cardiopulmonary resuscitation started, but unfortunately, the patient didn’t regain spontaneous circulation. Death was declared at 21:59.

3. Discussion

Ischemic hepatitis occurs in septic shock, cardiac failure, or respiratory failure due to decreased systemic blood flow and hypoperfusion [1]. Prolonged Prothrombin Time (PT) and elevated INR are often observed among patients with hepatic injury as the production of coagulation factors, including factors II, VII, IX, and X are decreased due to liver dysfunction, resulting in coagulopathy [2,3].

Our patient had ischemic hepatitis induced coagulopathy, which was induced by cardiac tamponade (confirmed through echocardiography), and hence, he was planned for emergency pericardiocentesis given his current hemodynamic instability as per the latest European Society of Cardiology Guidelines for the diagnosis and management of pericardial diseases [5]. To perform the pericardiocentesis, the coagulopathy needs to be corrected as it is considered a relative contraindication to the procedure [6]. Moreover, the American Association for the Study of Liver Diseases guidelines for the management of acute liver failure recommends the correction of coagulopathy in hemorrhage or before an invasive procedure [7]. For that, the patient already received eight units of FFP over two days and one dose of vitamin K 10 mg intravenous; however, the patient’s INR did not normalize.

Although FFP contains coagulation factors, inhibitors of coagulation, and fibrinolytic factors, FFP failed to reduce bleeding risk among patients with liver disease, and it is associated with volume overload, increased portal pressure, and transfusion-related reactions [8]. Alternatively, PCCs which contain four coagulation

| Table 1 |
|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| INR | PT (seconds) | Serum Creatinine (umol/L) | Blood urea nitrogen (mmol/L) | ALT (U/L) | AST (U/L) | Lactate (mmol/L) | Potassium (mmol/L) |
| 1.7 | 19.3 | 715 | 27 | 49 | 69 | 2.4 | 6.2 |

MICU: medical intensive care unit, INR: international normalized ratio, PT: prothrombin time, ALT: alanine transaminase, AST: aspartate aminotransferase.

| Table 2 |
|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Time | INR | PT (seconds) | Serum Creatinine (umol/L) | Blood urea nitrogen (mmol/L) | ALT (U/L) | AST (U/L) | Lactate (mmol/L) | Potassium (mmol/L) |
| 05:46 | 2 | 22.5 | 581 | 22.7 | 1729 | 1772 | 4.5 | 5.7 |
| 12:00 | 2 | 22.5 | 23.8 | 1729 | 1772 | 4.5 | 5.7 |
| 13:21 | 2 | 23.8 | 25.8 | 23.8 | 25.8 | 4.5 | 5.7 |
| 15:47 | 1.9 | 21.2 | 529 | 19.2 | 14,15, 18 | 6.9 |

MICU: medical intensive care unit, INR: international normalized ratio, PT: prothrombin time, ALT: alanine transaminase, AST: aspartate aminotransferase.

Fig. 1. INR trend before and after administration of activated prothrombin complex. INR: international normalized ratio, FFP: fresh frozen plasma, PCC: prothrombin complex concentrate.
factors (II, VII, IX, X) and proteins C and S could be an option for this patient. To date, four forms of PCCs are available, and they vary in the VII clotting factor content and its activation status, and heparin existence, as shown in Table 3 below [9–13].

The available PCC at our hospital is FEIBA, which is an activated 4 factor PCC that is approved by FDA in 1986 for patients with Hemophilia A and B for bleeding control and prevention, including perioperative bleeding and routine prophylaxis [11]. FEIBA is the only PCC that has an activated factor VII; however, it is associated with an increased risk of thrombosis, and especially that it lacks heparin [9,11].

The use of FEIBA among patients with ischemic hepatitis induced coagulopathy has not been evaluated yet; however, the use of Kcentra, which is an inactivated 4 factor PCC that contains heparin, was recently evaluated among patients with liver disease in a small retrospective study [4]. The study included 81 patients, of whom 31 patients had documented liver disease, and only 4 patients had an acute liver injury, compared to 54 patients without liver disease. The baseline INR was 2.8 among patients with liver disease, and 2.6 among patients without liver disease. Correction of INR to less than 1.5 within 48 h of Kcentra administration was achieved in 6 patients (~19%) in the liver disease arm compared to 44 patients (~82%) in the second arm: p < 0.01. In our case, the administration of activated PCC was effective in reducing the INR from 2.3 to 1.9, which allowed us to perform this high-risk procedure successfully.

Table 3  Characteristics of different PCC products.

| PCC Brand names       | Activated | Factor II | Factor VII | Factor IX | Factor X | Heparin |
|-----------------------|-----------|-----------|------------|-----------|----------|---------|
| Kcentra/Beriplex (Four-factor PCC)<sup>a</sup> | No        | Yes       | Yes        | Yes       | Yes      | Yes     |
| FEIBA                 | Yes       | Yes       | Yes (activated) | Yes       | Yes      | No      |
| Behbulin (Three-factor PCC)<sup>b</sup>  | No        | Yes       | Minimal    | Yes       | Yes      | Yes     |
| Protifilin (Three-factor PCC)<sup>b</sup> | No        | Yes       | Minimal    | Yes       | Yes      | No      |

PCC: prothrombin complex concentrate.

<sup>a</sup> Considered a four-factor PCC (4PCC) because of a significant amount of factor VII.

<sup>b</sup> Considered as three factors because of limited amounts of factor VII.

4. Conclusion

Given the need for urgent pericardiocentesis in view of hemodynamic instability, coagulopathy due to ischemic liver injury despite the use of vitamin K and FFP could be corrected with the use of activated PCC.

This manuscript was written in line with the SCARE 2020 Guideline [14].

Conflicts of interest

All authors report no conflict of interest.

Funding

This case report has no funds.

Ethical approval

This case report was approved by Hamad Medical Corporation Medical research center under number of: MRC-04-20-110.

Consent

Consent was accepted to be waived by Hamad Medical Corporation Medical Research Center (institutional review board), as the patient deceased, no available next of kin, and no patient images or videos were shared.

Author contribution

Hassan Mitwalla: the conception and design of the study, acquisition of data, drafting the article, and approved the final manuscript.

Ala Rahhal: drafting the article and approved the final manuscript.

Amr Fahmi: the conception and design of the study, acquisition of data, drafting the article, and approved the final manuscript.

Dore Ananthegowda: the conception and design of the study and approved the final manuscript.

Registration of Research Studies

Not applicable.

Guarantor

Hassan Abdallah H Mitwalla.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Acknowledgements

Open Access funding provided by the Qatar National Library.

References

[1] R.K. Seeto, B. Penn, D.C. Rockey, Ischemic hepatitis: clinical presentation and pathogenesis, Am. J. Med. 109 (2) (2000) 109–113.
[2] P.G. Northrup, S.H. Caldwell, Coagulation in liver disease: a guide for the clinician, Clin. Gastroenterol. Hepatol. 11 (9) (2013) 1064–1074.
[3] A. Tripodi, P.M. Mannucci, The coagulopathy of chronic liver disease, N. Engl. J. Med. 362 (2) (2011) 147–156.
[4] W.T. Huang, W.C. Kang, K.L. Derry, et al., Four-factor prothrombin complex concentrate for coagulopathy reversal in patients with liver disease, Clin. Appl. Thromb. Hemost. 23 (November (8)) (2017) 1028–1035.
[5] Y. Adler, P. Charron, M. Imaizio, et al., 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS), Eur. Heart J. 36 (2015) 2921.
[6] C. De Carlisi, S. Maggiolini, Pericardiocentesis in cardiac tamponade: indications and practical aspects, Eur. Soc. Cardiol. 15 (2017), Available at https://www.escardio.org/journals/E-Journal-of-Cardiology-Practice/Volume-15/Pericardiocentesis-in-cardiac-tamponade-indications-and-practical-aspects.
[7] J. Polson, W.M. Lee, R.T. Strausitz, AASLD position paper: the management of acute liver failure: update 2011 American Association for the Study of Liver Disease, Hepatology 41 (5) (2011) 1179–1197.
[8] P.M. Mannucci, Abnormalities of hemostasis tests in chronic liver disease: clinically relevant? in: L.V. Bavino, R.D. Franchis (Eds.), Portal Hypertension, Blackwell Publishing, Oxford, UK, 2006, pp. 40–60.
[9] M. Franchini, G. Lippi, Prothrombin complex concentrates: an update Blood Transfus. 8 (2010) 149–154.
[10] Four-Factor (II, VII, IX, X) Prothrombin Complex Concentrate (Kcentra) [Prescribing Information], VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives, 2015, March.
[11] FEIBA (Anti-Inhibitor Coagulant Complex) [Prescribing Information], Baxalta US Inc, Westlake Village, CA, 2017, April.
[12] Bebulin Prescribing Information, Baxter Healthcare Corporation, Westlake Village, CA, 2015, September.
[13] Profilnine Prescribing Information, Grifols Biologicals, Inc., Los Angeles, CA, 2014, May.
[14] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, for the SCARE Group, The SCARE 2020 guideline: updating consensus Surgical Case REport (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230.

Open Access
This article is published Open Access at sciedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.